Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Literature DB >> 10103211

Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

D Rodoni¹, F Hänni, C M Gerber, M Cottagnoud, K Neftel, M G Täuber, P Cottagnoud.

Abstract

Trovafloxacin, a new fluoroquinolone, produced bactericidal activity (-0.33 +/- 0.13 delta log10 CFU/ml.h; intravenously [i.v.] administered dose, 15 mg/kg) comparable to that of vancomycin (-0.39 +/- 0.18 delta log10 CFU/ml.h; i.v. admininistered dose, 20 mg/kg) in the treatment of experimental meningitis in rabbits due to a pneumococcal strain highly resistant to penicillin (MIC of penicillin G, 4 micrograms/ml). The combination of both drugs significantly increased (P < 0.05) the killing rate (-0.60 +/- 0.23 delta log10 CFU/ml.h) compared to that produced by either monotherapy. These results were also confirmed in vitro.

Entities: Chemical Disease Mutation Species

Mesh：

Substances：

Year: 1999 PMID： 10103211 PMCID： PMC89237

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. A study of the genetic material determining an enzyme in Pneumococcus.

Authors: S LACKS; R D HOTCHKISS
Journal: Biochim Biophys Acta Date: 1960-04-22

2. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors: M M París; S M Hickey; M Trujillo; S Shelton; G H McCracken
Journal: Antimicrob Agents Chemother Date: 1995-06 Impact factor: 5.191

3. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors: G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

4. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors: J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal: Antimicrob Agents Chemother Date: 1990-12 Impact factor: 5.191

5. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors: M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal: Antimicrob Agents Chemother Date: 1993-06 Impact factor: 5.191

6. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors: B B Gooding; R N Jones
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

7. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors: I R Friedland; M Paris; S Ehrett; S Hickey; K Olsen; G H McCracken
Journal: Antimicrob Agents Chemother Date: 1993-08 Impact factor: 5.191

8. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors: R G Dacey; M A Sande
Journal: Antimicrob Agents Chemother Date: 1974-10 Impact factor: 5.191

9. Microbioassay of antimicrobial agents.

Authors: H J Simon; E J Yin
Journal: Appl Microbiol Date: 1970-04

10. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

Authors: R Nau; T Schmidt; K Kaye; J L Froula; M G Täuber
Journal: Antimicrob Agents Chemother Date: 1995-03 Impact factor: 5.191

13 in total

1. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors: F Fitoussi; C Doit; P Geslin; E Bingen
Journal: Antimicrob Agents Chemother Date: 1999-10 Impact factor: 5.191

2. Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.

Authors:
Journal: Curr Infect Dis Rep Date: 2000-10 Impact factor: 3.725

3. Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.

Authors: P Cottagnoud; F Acosta; M Cottagnoud; K Neftel; M G Täuber
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

4. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxaxin and ceftriaxone with or without vancomycin.

Authors: Allan R. Tunkel
Journal: Curr Infect Dis Rep Date: 2002-08 Impact factor: 3.725

5. Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis.

Authors: Philippe Cottagnoud; Fernando Acosta; Marianne Cottagnoud; Marc Pfister; Martin G Täuber
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

6. Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors: Philippe Cottagnoud; Cynthia M Gerber; Marianne Cottagnoud; Martin G Täuber
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

7. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.

Authors: V Rodriguez-Cerrato; F Ghaffar; J Saavedra; I C Michelow; R D Hardy; J Iglehart; K Olsen; G H McCracken
Journal: Antimicrob Agents Chemother Date: 2001-11 Impact factor: 5.191

8. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors: P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal: Eur J Clin Microbiol Infect Dis Date: 2003-10-14 Impact factor: 3.267

9. Fluoroquinolones in the Treatment of Meningitis.

Authors: Philippe Cottagnoud; Martin G. Täuber
Journal: Curr Infect Dis Rep Date: 2003-08 Impact factor: 3.725

10. Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin.

Authors: P Cottagnoud; M Cottagnoud; M G Täuber
Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191